Dr. Brad Vince of Vince & Associates Clinical Research Announces Award of Nearly $10 Million Contract from the National Institute on Drug Abuse
Vince & Associates Clinical Research
announced it has been awarded a contract with the
National Institute on Drug Abuse
, part of the
National Institutes of Health (NIH)
, to carry out clinical pharmacology studies to determine the pharmacokinetics and pharmacodynamics of new medication in humans.
This award is a five year contract with a ceiling value of $9,695,476 beginning September 2012. Vince and Associates will conduct clinical pharmacology studies to support the development of new medications for the treatment of substance abuse disorders.
“Our organization will research investigational medications to include new chemical entities, new biological products such as monoclonal antibodies, enzymes and vaccines as well as already approved drug products,” said
Dr. Brad Vince
, president and medical director of Vince & Associates Clinical Research. “Our organization is excited to work on clinical studies with NIDA that may benefit those struggling with substance abuse disorders.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
